NYSE:BMYPharmaceuticals
EU Sotyktu Approval Tests Bristol-Myers Squibb’s Immunology And Earnings Story
European Commission approves Sotyktu (deucravacitinib) for adults with active psoriatic arthritis.
First TYK2 inhibitor cleared for this indication in the European Union.
Label expansion adds a once daily oral option for patients with limited treatment choices.
Bristol-Myers Squibb (NYSE:BMY), trading at $56.25, now has an expanded EU label for Sotyktu that reflects its efforts in immunology. The stock is up 26.0% over the past year and 5.2% year to date, while longer multiyear returns have...